INT216107

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.08
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 30
Total Number 30
Disease Relevance 6.11
Pain Relevance 0.80

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
muscle 6
muscle fiber 2
Mouse 1
femoral artery 1
tail vein 1
Imraq1 (Mus musculus)
Pain Link Frequency Relevance Heat
Substantia nigra 5 95.20 Very High Very High Very High
Pyramidal cell 228 92.16 High High
Hippocampus 50 91.60 High High
Inflammation 42 58.88 Quite High
Eae 10 58.32 Quite High
ketamine 46 57.16 Quite High
sodium channel 7 48.72 Quite Low
isoflurane 12 39.84 Quite Low
imagery 139 37.44 Quite Low
corticosteroid 6 37.44 Quite Low
Disease Link Frequency Relevance Heat
Injury 91 99.84 Very High Very High Very High
Cytomegalovirus Infection 131 99.44 Very High Very High Very High
Disease 227 98.96 Very High Very High Very High
Tauopathy 200 98.04 Very High Very High Very High
Congenital Structural Myopathies 119 98.04 Very High Very High Very High
Dilated Cardiomyopathy 20 95.84 Very High Very High Very High
Alzheimer's Dementia 160 95.60 Very High Very High Very High
Sclerosis 20 92.92 High High
Amyloid Plaque 55 90.48 High High
Body Weight 58 90.08 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We attribute the differences between our results with AAV1 and those of prior studies [18,25] most likely related to the volume of perfusate [1 ml vs 100 ?
Gene_expression (results) of AAV1
1) Confidence 0.08 Published 2007 Journal J Transl Med Section Body Doc Link PMC2082019 Disease Relevance 0.33 Pain Relevance 0
The very large viral load required to achieve widespread AAV6 transduction using tail vein delivery in the mdx mouse would challenge current vector production methods, clearly limiting clinical application.
Gene_expression (transduction) of AAV6 in tail vein
2) Confidence 0.07 Published 2007 Journal J Transl Med Section Body Doc Link PMC2082019 Disease Relevance 0.08 Pain Relevance 0
A dose of 1 × 1011 vg (rAAV1, rAAV6, or rAAV8) was perfused through the femoral artery in 100 ?
Gene_expression (rAAV6) of rAAV1 in femoral artery
3) Confidence 0.07 Published 2007 Journal J Transl Med Section Body Doc Link PMC2082019 Disease Relevance 0.27 Pain Relevance 0.03
rAAV1, 6, or 8.MCK.micro-dystrophin vector was perfused (100 ?
Gene_expression (vector) of rAAV1
4) Confidence 0.07 Published 2007 Journal J Transl Med Section Body Doc Link PMC2082019 Disease Relevance 0.06 Pain Relevance 0
This could not be attributed to the biological activity of the vector preparation since direct muscle injection into the TA, performed in parallel with the vascular injections, resulted in robust and equivalent gene expression for all three serotypes at 1 month post injection; 94.0 ± 1.2% (rAAV1), 95.5 ± 0.7% (rAAV6), and 95.1 ± 0.6% (rAAV8) (Fig. 1B).
Gene_expression (expression) of rAAV1 in muscle
5) Confidence 0.07 Published 2007 Journal J Transl Med Section Body Doc Link PMC2082019 Disease Relevance 0.05 Pain Relevance 0
The production plasmids were: (i) pAAV.MCK.microdys, (ii) rep2-capX modified AAV helper plasmids encoding cap serotypes 1, 6, or an 8-like isolate, and (iii) an adenovirus type 5 helper plasmid (pAdhelper) expressing adenovirus E2A, E4 ORF6, and VA I/II RNA genes.
Gene_expression (expressing) of AAV
6) Confidence 0.06 Published 2007 Journal J Transl Med Section Body Doc Link PMC2082019 Disease Relevance 0.05 Pain Relevance 0
Expression of AAV-LSL-GFP is stable for months
Gene_expression (Expression) of AAV
7) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2289876 Disease Relevance 0 Pain Relevance 0.15
We characterized the time course and stability of GFP expression after AAV transfection in Pv-cre mice.
Gene_expression (transfection) of AAV
8) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2289876 Disease Relevance 0 Pain Relevance 0.14
Expression levels of individual AAV-transfected cells in Pv-cre mice were heterogeneous, even close to the injection site, as evident in the histogram plots in Figure 2a.
Gene_expression (transfected) of AAV
9) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2289876 Disease Relevance 0 Pain Relevance 0.10
GFP-expressing neurons transfected with AAV.LS1L.GFP and mCherry-expressing neurons transfected with AAV.LS2L.ChR2mCherry were visualized using the upright microscope described above and cells were patched using a 63× objective (NA 0.95) under near-infrared differential interference contrast optics.
Gene_expression (expressing) of AAV in optics
10) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2289876 Disease Relevance 0.16 Pain Relevance 0
These results indicate that the intrinsic physiological properties of interneurons were preserved after AAV transfection.
Gene_expression (transfection) of AAV in interneurons
11) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2289876 Disease Relevance 0 Pain Relevance 0
Expression levels of individual AAV-transfected cells in Pv-cre mice were heterogeneous, even close to the injection site, as evident in the histogram plots in Figure 2a.
Gene_expression (Expression) of AAV
12) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2289876 Disease Relevance 0 Pain Relevance 0.10
Generation of LSL.XFP AAV vectors
Gene_expression (Generation) of AAV
13) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2289876 Disease Relevance 0 Pain Relevance 0
Sweeney) and a similar loss of AAV mediated myostatin propeptide expression after six weeks in the highly regenerative alpha-sarcoglycan null model [20], [21].
Gene_expression (expression) of AAV
14) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2820101 Disease Relevance 0.15 Pain Relevance 0
The loss of AAV transduction over time is most likely due to muscle fiber turnover as evidenced by the loss of AAV mediated IGF expression after four months in mdx muscle (unpublished observations by E.R.
Gene_expression (expression) of AAV in muscle fiber
15) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2820101 Disease Relevance 0.16 Pain Relevance 0
Previous studies that have used antibodies directed against myostatin, propeptide injections or AAV mediated overexpression of an inhibitor have demonstrated increased muscle mass and absolute force production following 3–4 months of myostatin inhibition in young animals (1–3 months old) [3], [13], [14].
Gene_expression (overexpression) of AAV in muscle
16) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2820101 Disease Relevance 0.05 Pain Relevance 0
Qiao et al. recently reported that the AAV mediated expression of a mutated myostatin propeptide increases muscle size and improves pathology in mdx animals [14].
Gene_expression (expression) of AAV in muscle
17) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2820101 Disease Relevance 0.70 Pain Relevance 0
Confocal microscopic examination of AAV transduced muscle overexpressing myotubularin revealed considerably stronger signal at the triads and specific localization at the sarcolemma as well.
Gene_expression (overexpressing) of AAV in muscle
18) Confidence 0.01 Published 2008 Journal Human Molecular Genetics Section Body Doc Link PMC2441725 Disease Relevance 0.06 Pain Relevance 0
The abnormal membrane structures observed upon AAV-mediated myotubularin overexpression in muscle could result from an imbalance between membrane internalization and recycling during endocytosis.
Gene_expression (overexpression) of AAV in muscle
19) Confidence 0.01 Published 2008 Journal Human Molecular Genetics Section Body Doc Link PMC2441725 Disease Relevance 0.51 Pain Relevance 0
We have constructed an adeno-associated virus (AAV) vector expressing myotubularin in order to test its therapeutic potential in a XLMTM mouse model.
Gene_expression (expressing) of AAV
20) Confidence 0.01 Published 2008 Journal Human Molecular Genetics Section Abstract Doc Link PMC2441725 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox